Guard Therapeutics: A binary case with asymmetric upside - Redeye

Redeye initiates coverage of Guard Therapeutics, a clinical-stage biotech developing innovative therapies for diseases with high unmet needs, focusing on kidney protection at different events of stress. The company is nearing a decisive readout in its phase IIb POINTER study, evaluating RMC-035 as a renal protective agent during cardiac surgery, expected in Q4 2025e. While facing a binary event, we believe the modest valuation offers an asymmetric risk/reward opportunity.

Länk till analysen i sin helhet: https://www.redeye.se/research/1127309/guard-therapeutics-a-binary-case-with-asymmetric-upside?utm_source=finwire&utm_medium=RSS